Migoka (1731-TW) White (4108-TW) Stated that it will launch a clinical trial of the cytokine storm that inhibits the production of new coronary pneumonia and develop new adapted drugs. Currently, it has contacted the clinical trial commissioning service company and the U.S. Medical Center, and will apply for emergency clinical trial permission to the U.S. FDA in the future.
General Manager Zheng Jianxin pointed out that under normal circumstances, the human immune mechanism can trigger an appropriate inflammatory response to clear the damaged cells infected by the virus. However, the virus breaks through the immune system, replicates in large numbers, and destroys the immune regulation mechanism, which will lead to excessive The inflammatory response triggers a cytokine storm, which has also become the most deadly cause of new coronary pneumonia.
International medical journals in the new field of immunomedicine papers mentioned that compared with patients with mild cases of new coronary pneumonia, severely ill patients are more often found over-expressed inflammatory cytokines, and a large number of pro-inflammatory cells in the body, such as macrophages and neutrophils Etc., causing damage to blood and lymphocytes.
White’s development of a cancer-induced fatigue drug, White Blood Po, has been proven in cancer immunotherapy that the drug can help increase the ratio of human neutrophils to lymphocytes and can normalize excessive inflammation. Therefore, the development of new indications will be initiated. drug.
Chairman Li Yili pointed out that at the beginning of this year, an increase of 350 million yuan was completed. One of the funds is to suppress the cytokine storm clinical trial of new coronary pneumonia. At present, he has contacted the clinical trial commissioning service company and the U.S. Medical Center and will report to the U.S. FDA as soon as possible. Submit an application for emergency clinical trial permit, start international clinical trials and develop new indication drugs.